Sazonova D, Perepelova M, Shutova A, Nikankina L, Kolesnikova G, Pigarova E
Probl Endokrinol (Mosk). 2024; 70(5):34-39.
PMID: 39509634
PMC: 11610638.
DOI: 10.14341/probl13390.
Mantovani B, Indirli R, Lanzi V, Petria I, Arosio M, Mantovani G
Endocrinol Diabetes Metab Case Rep. 2024; 2024(4).
PMID: 39437836
PMC: 11558970.
DOI: 10.1530/EDM-23-0144.
Nishiyama N, Hattori N, Aisaka K, Ishihara M, Saito T
Clin Chem Lab Med. 2024; 62(11):2162-2168.
PMID: 38680064
DOI: 10.1515/cclm-2024-0235.
Chiardi I, Rotondi M, Cantu M, Keller F, Trimboli P
J Pers Med. 2023; 13(10).
PMID: 37888082
PMC: 10608259.
DOI: 10.3390/jpm13101471.
Cozzi R, Auriemma R, De Menis E, Esposito F, Ferrante E, Iati G
Endocr Metab Immune Disord Drug Targets. 2023; 23(12):1459-1479.
PMID: 37171003
PMC: 10556400.
DOI: 10.2174/1871530323666230511104045.
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.
Cozzi R, Ambrosio M, Attanasio R, Battista C, Bozzao A, Caputo M
Eur J Endocrinol. 2022; 186(3):P1-P33.
PMID: 35000899
PMC: 8859924.
DOI: 10.1530/EJE-21-0977.
Altered immunoglobulin G glycosylation in patients with isolated hyperprolactinaemia.
Hirschberg D, Ekman B, Wahlberg J, Landberg E
PLoS One. 2021; 16(2):e0247805.
PMID: 33635916
PMC: 7909626.
DOI: 10.1371/journal.pone.0247805.
Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia.
Yu C, Fan F, Hu S, Meng L, Xu D, Wang J
J Clin Lab Anal. 2020; 34(11):e23456.
PMID: 32597541
PMC: 7676205.
DOI: 10.1002/jcla.23456.
Prevalence and reproductive manifestations of macroprolactinemia.
Kalsi A, Halder A, Jain M, Chaturvedi P, Sharma J
Endocrine. 2018; 63(2):332-340.
PMID: 30269265
DOI: 10.1007/s12020-018-1770-6.
Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues.
Saleem M, Martin H, Coates P
Clin Biochem Rev. 2018; 39(1):3-16.
PMID: 30072818
PMC: 6069739.
Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause.
Palubska S, Adamiak-Godlewska A, Winkler I, Romanek-Piva K, Rechberger T, Gogacz M
Prz Menopauzalny. 2017; 16(1):1-7.
PMID: 28546800
PMC: 5437053.
DOI: 10.5114/pm.2017.67364.
Sexual function and depressive symptoms in young women with elevated macroprolactin content: a pilot study.
Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B
Endocrine. 2016; 53(1):291-8.
PMID: 26902871
PMC: 4901097.
DOI: 10.1007/s12020-016-0898-5.
Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study.
Kim S, Park Y
PLoS One. 2013; 8(12):e82749.
PMID: 24312671
PMC: 3846723.
DOI: 10.1371/journal.pone.0082749.
Macroprolactinemia: diagnostic, clinical, and pathogenic significance.
Shimatsu A, Hattori N
Clin Dev Immunol. 2013; 2012:167132.
PMID: 23304187
PMC: 3529459.
DOI: 10.1155/2012/167132.
Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease.
Lewandowski K, Gasior-Perczak D, Kowalska A, Lewinski A
Thyroid Res. 2012; 5(1):20.
PMID: 23244563
PMC: 3542033.
DOI: 10.1186/1756-6614-5-20.
Macroprolactinemia: new insights in hyperprolactinemia.
Kasum M, Oreskovic S, Zec I, Jezek D, Tomic V, Gall V
Biochem Med (Zagreb). 2012; 22(2):171-9.
PMID: 22838183
PMC: 4062336.
DOI: 10.11613/bm.2012.020.
Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.
Tamer G, Telci A, Mert M, Uzum A, Aral F, Tanakol R
Endocrine. 2011; 41(1):138-43.
PMID: 21959531
DOI: 10.1007/s12020-011-9536-4.
Macroprolactinemia, like hyperprolactinemia, may promote platelet activation.
Anaforoglu I, Ertorer M, Kozanoglu I, Unal B, Haydardedeoglu F, Bakiner O
Endocrine. 2010; 37(2):294-300.
PMID: 20960266
DOI: 10.1007/s12020-009-9304-x.
